Cost-Effectiveness of Pembrolizumab for the Adjuvant ...

Most melanoma patients are diagnosed with early-stage disease, but recurrence is seen in many cases (15–40%) despite the original favorable prognosis [8–10]. There are also a considerable number of patients first diagnosed in advanced stage III or IV disease. [2] For resectable stage III … ................
................